KDM1A and breast carcinoma: Furthermore, to address the enormous potential of SETDB1 targeting in breast cancer, combination studies combining SETDB1 drugs either alone or in combination with other classes of epigenetic drugs such as LSD1 inhibitors, either alone or with immunotherapy or chemotherapy drugs, are urgently required.